

(43) International Publication Date 28 December 2000 (28.12.2000)

(10) International Publication Number WO 00/78796 A2

(51) International Patent Classification7:

C07K 7/00

- (21) International Application Number: PCT/US00/17509
- (22) International Filing Date:
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/140,913 60/213,068

24 June 1999 (24.06.1999) US 21 June 2000 (21.06.2000)

22 June 2000 (22.06.2000)

- (71) Applicant (for all designated States except US): MALLINCKRODT INC. [US/US]; 675 McDonnell Boulevard, P.O. Box 5840, St. Louis, MO 63134 (US).
- (71) Applicants and
- (72) Inventors: SRINIVASAN, Ananthachari [US/US]; 332 Woodmere Drive, St. Charles, MO 63303 (US). ERION, Jack, L. [US/US]; 379 Woodmere Nook Ct., St. Charles, MO 63303 (US). SCHMIDT, Michelle, A. [US/US]; 417 Hickory Manor, Belleville, IL 62223 (US).

- (74) Agent: BOONE, Jeffrey, S.; Mallinckrodt Inc., 675 Mc-Donnell Boulevard, P.O. Box 5840, St. Louis, MO 63134 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU. LV, MA. MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE. CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Ţ

ũ

N

(57) Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.